ClinicalTrials.gg
CompletedNCT00672958Updated Dec 13, 2013Results posted

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 33 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-13.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
14th of 54
600 · median 413
Started
2008
with 5 others
Phase 3
31 of 54
1 open now
Registered
3rd of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 14th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 3rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.

Read the detailed description

The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took vortioxetine.

The study enrolled 600 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 5 mg
  • Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in the United States. The overall time to participate in this study was approximately 94 days. Participants made 8 visits to the clinic, and were contacted by telephone 1 week, 2 weeks, and 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Depression
  • Drug Therapy
  • Major Depressive Episode
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suffers from a major depressive episode (MDE) as the primary diagnosis according to , 4th Edition, Text Revision (DSM-IV-TR) criteria.
  • The reported duration of the current MDE is at least 3 months.
  • Has a Montgomery Åsberg Depression Rating Scale total score greater than or equal to 30.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Has received any compound less than 30 days before Screening or 5 half-lives prior to Screening, whichever is longer.
  • Has received Lu AA21004 in a previous clinical study.
  • Has 1 or more the following:

    • Any current psychiatric disorder other than major depressive disorder as defined in the (as assessed by the Mini International Neuropsychiatric Interview)
    • Current or past history of: manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder that might compromise the study.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Narcotic analgesics
    • Nonsteroidal anti-inflammatory drugs
    • Rifampin
    • Macrolide antibiotics
    • Hormones (only thyroid hormone replacement, [oral, patch], estrogen and progesterone replacement therapy are allowed in chronic use)
    • Hypoglycemic agents (chronic use is allowed)
    • Insulin (chronic use is allowed)
    • Systemic
    • Quinidine
    • Antineoplastics
    • Antiobesity agents
  • Has a significant risk of suicide according to the investigator's opinion or has a score greater than or equal to 5 on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
  • The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
  • Has an , aspartate aminotransferase or total level greater than 1.5 times the .
  • Has a serum creatinine greater than 1.5 times the upper limits of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include basal cell or Stage I squamous cell carcinoma of the skin.
  • Has clinically significant abnormal vital signs as determined by the investigator.
  • Has an abnormal determined by the central reader and confirmed as clinically significant by the investigator.
  • Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant.
  • Has a thyroid stimulating hormone value outside the normal range at Screening Visit that is determined to be clinically significant by the investigator.
  • Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  • Has previously enrolled in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
600 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine

    Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.

    Drug: Vortioxetine

Interventions

  • Encapsulated immediate-release tablets.

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching capsules.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.

    Time frame: Baseline and Week 6

  2. Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 3, 4 and 5

Secondary outcomes

  1. Percentage of Responders in HAM-D24 Total Score by Study Visit

    A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.

  2. Percentage of Participants in MADRS Remission at Week 6

    Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Week 6

  3. Percentage of Participants With a Sustained Response in HAM-D24

    A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.

    Time frame: Baseline to Week 6

  4. Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.

  5. Change From Baseline in Hamilton Anxiety Scale (HAM-A)

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4 and 6.

  6. Change From Baseline in Clinical Global Impression Scale-Severity of Illness

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.

  7. Clinical Global Impression Scale-Global Improvement Scale

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 3, 4, 5 and 6.

  8. Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)

    The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 4 and 6.

  9. Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 6

  10. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 6

  11. Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 6

07

Results

Posted Dec 13, 2013

Participant flow

Participants took part in the study at 47 investigative sites in the United States from 07 April 2008 to 12 November 2008.

Participant flow — Overall Study
MilestonePlaceboVortioxetine
Started300300
Safety set298299
Full analysis set286292
Completed236244
Not completed6456
Withdrew: Adverse event119
Withdrew: Lack of efficacy611
Withdrew: Non-compliance with study drug23
Withdrew: Protocol deviations115
Withdrew: Voluntary withdrawal128
Withdrew: Lost to follow-up2217
Withdrew: Reason not specified03

Outcome measures

PrimaryChange From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6
scores on a scalePlaceboVortioxetine
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6-13.87 ± 0.662-14.61 ± 0.650
Statistical analysis
  • Placebo vs Vortioxetine · ANCOVA · p = 0.407 (Pre-specified sequential statistical testing procedure indicates that when p-value for change from baseline in HAMD-24 at Week 6 \>0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -0.74 · 95% CI -2.48 to 1.01Analysis of covariance (ANCOVA), with treatment and center as fixed factors and baseline HAM-D24 as a covariate.
PrimaryChange From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 3, 4 and 5
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine
Week 1 (n=281, 286)-6.03 ± 0.394-5.96 ± 0.387
Week 2 (n= 286, 291)-9.30 ± 0.505-9.05 ± 0.496
Week 3 (n= 286, 292)-11.05 ± 0.545-11.73 ± 0.536
Week 4 (n= 286, 292)-12.33 ± 0.579-12.66 ± 0.568
Week 5 (n=286, 292)-13.11 ± 0.628-13.98 ± 0.617
Statistical analysis
  • Placebo vs Vortioxetine · ANCOVA · p = 0.901 · Ls mean difference: 0.07 · 95% CI -0.97 to 1.10ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.
  • Placebo vs Vortioxetine · ANCOVA · p = 0.701 · Ls mean difference: 0.26 · 95% CI -1.07 to 1.59ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.
  • Placebo vs Vortioxetine · ANCOVA · p = 0.356 · Ls mean difference: -0.68 · 95% CI -2.11 to 0.76ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.
  • Placebo vs Vortioxetine · ANCOVA · p = 0.670 · Ls mean difference: -0.33 · 95% CI -1.85 to 1.19ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.
  • Placebo vs Vortioxetine · ANCOVA · p = 0.304 · Ls mean difference: -0.87 · 95% CI -2.52 to 0.79ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.
SecondaryPercentage of Responders in HAM-D24 Total Score by Study Visit

A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-D24 Total Score by Study Visit
percentage of participantsPlaceboVortioxetine
Week 1 (n=281, 286)7.87.0
Week 2 (n=286, 291)23.821.0
Week 3 (n=286, 292)31.832.9
Week 4 (n=286, 292)39.237.0
Week 5 (n=286, 292)44.443.8
Week 6 (n=286, 292)46.246.2
SecondaryPercentage of Participants in MADRS Remission at Week 6

Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Week 6
percentage of participantsPlaceboVortioxetine
Percentage of Participants in MADRS Remission at Week 632.229.1
SecondaryPercentage of Participants With a Sustained Response in HAM-D24

A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.

Time frame:
Baseline to Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Response in HAM-D24
percentage of participantsPlaceboVortioxetine
Percentage of Participants With a Sustained Response in HAM-D2421.019.5
SecondaryChange From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
scores on a scalePlaceboVortioxetine
Week 1 (n=281, 286)-6.88 ± 0.418-6.38 ± 0.412
Week 2 (n=286, 291)-10.57 ± 0.530-9.82 ± 0.523
Week 3 (n=286, 292)-12.48 ± 0.583-12.76 ± 0.575
Week 4 (n=286, 292)-13.72 ± 0.624-13.70 ± 0.615
Week 5 (n=286, 292)-14.40 ± 0.673-15.12 ± 0.664
Week 6 (n=286, 292)-15.48 ± 0.708-15.80 ± 0.698
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A)

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4 and 6.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A)
scores on a scalePlaceboVortioxetine
Week 1 (n=281, 286)-3.25 ± 0.288-3.21 ± 0.284
Week 2 (n=286, 291)-4.92 ± 0.343-4.77 ± 0.338
Week 4 (n=286, 292)-6.52 ± 0.393-6.88 ± 0.387
Week 6 (n=286, 292)-7.60 ± 0.419-7.84 ± 0.413
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness
scores on a scalePlaceboVortioxetine
Week 1 (n=281, 286)-0.47 ± 0.045-0.40 ± 0.044
Week 2 (n=286, 291)-0.82 ± 0.061-0.82 ± 0.060
Week 3 (n=286, 292)-1.07 ± 0.069-1.08 ± 0.067
Week 4 (n=286, 292)-1.25 ± 0.073-1.20 ± 0.072
Week 5 (n=286, 292)-1.28 ± 0.079-1.36 ± 0.077
Week 6 (n=286, 292)-1.46 ± 0.085-1.46 ± 0.083
SecondaryClinical Global Impression Scale-Global Improvement Scale

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 3, 4, 5 and 6.
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement Scale
scores on a scalePlaceboVortioxetine
Week 1 (n=281, 286)3.38 ± 0.0483.46 ± 0.047
Week 2 (n=286, 291)3.09 ± 0.0623.08 ± 0.061
Week 3 (n=286, 292)2.90 ± 0.0662.84 ± 0.065
Week 4 (n=286, 292)2.74 ± 0.0702.75 ± 0.069
Week 5 (n=286, 292)2.74 ± 0.0732.65 ± 0.071
Week 6 (n=286, 292)2.61 ± 0.0762.57 ± 0.075
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)

The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 4 and 6.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
scores on a scalePlaceboVortioxetine
Week 1 (n=279, 286)-2.81 ± 0.214-2.73 ± 0.210
Week 4 (n=284, 292)-4.18 ± 0.272-4.05 ± 0.267
Week 6 (n=284, 292)-4.56 ± 0.313-4.97 ± 0.307
SecondaryChange From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6
scores on a scalePlaceboVortioxetine
Physical functioning5.47 ± 1.2776.87 ± 1.264
Role - physical11.73 ± 1.56914.41 ± 1.549
Bodily pain10.77 ± 1.46010.39 ± 1.445
General health7.65 ± 0.9857.37 ± 0.975
Vitality18.00 ± 1.45517.34 ± 1.440
Social functioning21.34 ± 1.68722.01 ± 1.667
Role - emotional19.43 ± 1.75620.76 ± 1.732
Mental health18.98 ± 1.40120.00 ± 1.385
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6
scores on a scalePlaceboVortioxetine
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6-6.61 ± 0.548-6.69 ± 0.557
SecondaryHealth Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 6
Reported as:
Number · participants
Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
participantsPlaceboVortioxetine
Baseline: Any resource use8277
Baseline: Any hospitalization-related services10
Baseline: Hospitalization related to depression10
Baseline: Any sick leave1621
Baseline: Sick leave related to depression913
Week 6: Any resource use5841
Week 6: Any hospitalization-related service31
Week 6: Hospitalization related to depression00
Week 6: Any sick leave77
Week 6: Sick leave related to depression32

Adverse events

Collected over Treatment-emergent adverse events are defined as adverse events whose onset occurred or intensity increased after the first dose of double-blind study drug through 30 days after permanent discontinuation of double-blind study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/298 (1.3%)142/298 (47.7%)
Vortioxetine—7/299 (2.3%)168/299 (56.2%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlaceboVortioxetine
Puncture site infectionInfections and infestations1/2980/299
Laryngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2980/299
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2980/299
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/2980/299
Drug hypersensitivityImmune system disorders0/2981/299
Herpes zosterInfections and infestations0/2981/299
InjuryInjury, poisoning and procedural complications0/2981/299
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2981/299
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2981/299
Cerebrovascular accidentNervous system disorders0/2981/299
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboVortioxetine
NauseaGastrointestinal disorders28/29857/299
HeadacheNervous system disorders45/29851/299
DiarrhoeaGastrointestinal disorders21/29834/299
Dry mouthGastrointestinal disorders19/29825/299
DizzinessNervous system disorders22/29819/299
Abdominal painGastrointestinal disorders3/29812/299
SomnolenceNervous system disorders10/29811/299
DyspepsiaGastrointestinal disorders10/2985/299
InsomniaPsychiatric disorders9/2986/299
ConstipationGastrointestinal disorders6/2989/299

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetineTotal
Mean42.4 ± 12.7042.5 ± 13.0442.4 ± 12.86
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetineTotal
Female164186350
Male136114250
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetineTotal
Caucasian (White, including Hispanic)216209425
Black7881159
Asian4812
American Indian or Alaska Native213
Native Hawaiian/ Other Pacific Islander011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetineTotal
Hispanic/Latino363470
Non-Hispanic/Non-Latino264266530
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetineTotal
United States300300600
Weight
Weight(kg)PlaceboVortioxetineTotal
Mean89.53 ± 23.32686.63 ± 23.52888.08 ± 23.453
Height
Height(cm)PlaceboVortioxetineTotal
Mean170.36 ± 9.815168.67 ± 9.815169.51 ± 9.843
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboVortioxetineTotal
Mean30.84 ± 7.67530.48 ± 8.21730.66 ± 7.946

7 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • Birmingham, Alabama, United States
  • Cerritos, California, United States
  • Encino, California, United States
  • Fresno, California, United States
  • San Diego, California, United States
  • Farmington, Connecticut, United States
  • Jacksonville, Florida, United States
  • North Miami, Florida, United States
  • Tampa, Florida, United States
  • Hoffman Estate, Illinois, United States
  • Lafayette, Indiana, United States
  • Valparaiso, Indiana, United States
  • Shreveport, Louisiana, United States
  • St. Paul, Minnesota, United States
  • Florissant, Missouri, United States
  • St. Charles, Missouri, United States
  • Las Vegas, Nevada, United States
  • Rochester, New York, United States
  • Dayton, Ohio, United States
  • Toledo, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Lincoln, Rhode Island, United States
  • North Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Lake Jackson, Texas, United States
  • Wichita Falls, Texas, United States
  • Brown Deer, Wisconsin, United States
  • Middleton, Wisconsin, United States
  • Hull, Quebec, Canada
  • Mexico, D.F., Mexico
  • San Luis Potosi, Mexico
09

References and documents

Publications

  • Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21. doi: 10.1017/S1461145712000727. Epub 2012 Sep 11. PubMed 22963932 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2008
First posted
May 6, 2008
Start
Apr 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Dec 13, 2013
Last update
Dec 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00672958
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
May 6, 2008
Start date
Apr 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 13, 2013
Last update
Dec 13, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion